Compared to placebo what was the result of rivastigmine capsule and patch on AD Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) score?
Significant benefits were seen on the ADCS-ADL in 9.5 mg/24 h patch- and capsule-treated patients with, but not without, VRF.